| Autor: |
Borén J; Wallenberg Laboratory, Sahlgrenska University Hospital, Gothenburg, Sweden.; Department of Molecular and Clinical Medicine, University of Gothenburg, Gothenburg, Sweden; email: jan.boren@wlab.gu.se., Taskinen MR; Research Programs Unit, Clinical and Molecular Metabolism, University of Helsinki, Helsinki, Finland., Packard CJ; Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, United Kingdom. |
| Jazyk: |
angličtina |
| Zdroj: |
Annual review of nutrition [Annu Rev Nutr] 2024 Aug; Vol. 44 (1), pp. 179-204. Date of Electronic Publication: 2024 Aug 12. |
| DOI: |
10.1146/annurev-nutr-062222-020716 |
| Abstrakt: |
Recent advances in human genetics, together with a substantial body of epidemiological, preclinical and clinical trial evidence, strongly support a causal relationship between triglyceride-rich lipoproteins (TRLs) and atherosclerotic cardiovascular disease. Consequently, the secretion and metabolism of TRLs have a significant impact on cardiovascular health. This knowledge underscores the importance of understanding the molecular mechanisms and regulation of very-low-density lipoprotein (VLDL) and chylomicron biogenesis. Fortunately, there has been a resurgence of interest in the intracellular assembly, trafficking, degradation, and secretion of VLDL, leading to many ground-breaking molecular insights. Furthermore, the identification of molecular control mechanisms related to triglyceride metabolism has greatly advanced our understanding of the complex metabolism of TRLs. In this review, we explore recent advances in the assembly, secretion, and metabolism of TRLs. We also discuss available treatment strategies for hypertriglyceridemia. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
